Biomea Fusion (BMEA) Stock
Clinical stage biotech company targeting cancer and metabolic disease. Here's the price, business snapshot, and what's worth knowing about Biomea Fusion in August 2026.
Biomea Fusion Inc (BMEA) is a clinical-stage biotechnology company developing small-molecule therapies, primarily targeting oncology and metabolic disease programmes. Investors should know it is early-stage: product candidates are typically in preclinical or clinical trials, so progress depends heavily on trial results, regulatory review and potential partnerships or licensing deals. With a market capitalisation of about $110.22M, Biomea is a small, relatively illiquid stock where share prices can move sharply on news. Biotech investing can offer upside if molecules demonstrate safety and efficacy, but it also carries binary and timing risks — clinical setbacks, regulatory delays or financings can materially affect value. This summary is educational only and not personalised financial advice. Consider diversification, time horizon and risk tolerance before researching further; consult a regulated adviser for tailored recommendations. Past performance does not predict future results and capital is at risk.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying BIOMEA FUSION INC's stock, with a target price of $7 indicating strong potential growth.
Financial Health
Biomea Fusion Inc. shows reasonable cash flow and book value, indicating stability but room for improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring BMEA
Oral Obesity Treatments: Investment Theme Explained
Novo Nordisk has launched the first oral GLP-1 weight loss medication, Wegovy, representing a major evolution in the obesity treatment landscape. This shift from injections to pills creates an investment opportunity in pharmaceutical innovators and the digital health companies enabling broad access.
Published: 6 January 2026
Explore BasketObesity Drug Pricing | Pharma Investment Theme
New agreements with Eli Lilly and Novo Nordisk are set to dramatically lower the cost of popular weight-loss drugs, making them accessible to millions through Medicare. This creates an investment opportunity centered on the major pharmaceutical companies involved and the broader supply chain that will support the expected surge in demand.
Published: 8 November 2025
Explore BasketObesity Drug Stocks: Medicare Coverage Trade-offs
A new agreement between the Trump administration, Eli Lilly, and Novo Nordisk will dramatically lower the cost of GLP-1 weight loss drugs and expand Medicare coverage. This move is expected to significantly increase patient access and boost sales, creating opportunities for the drug manufacturers and their key suppliers.
Published: 7 November 2025
Explore BasketBiotech Buyout Wave Targets Obesity Market 2025
Pfizer's bid for obesity drug maker Metsera has turned into a legal battle after a counteroffer from Novo Nordisk, highlighting the fierce competition in the weight-loss market. This intense M&A activity signals that other biotech companies with promising obesity treatments could become the next valuable acquisition targets.
Published: 1 November 2025
Explore BasketWeight-Loss Drug M&A: Valuation Risk Concerns
Novo Nordisk's superior bid for Metsera has ignited a bidding war with Pfizer, highlighting the intense M&A activity in the obesity drug market. This theme focuses on other biotech companies with promising weight-loss therapies that could become the next acquisition targets.
Published: 31 October 2025
Explore BasketOzempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketWeight-Loss Drug Shakeup: What's Next for Biotechs?
Following former President Trump's pledge to slash prices for popular weight-loss drugs, uncertainty has hit major pharmaceutical stocks. This theme identifies competitor firms and biotechs that could gain an edge as the pricing landscape for metabolic drugs shifts.
Published: 18 October 2025
Explore BasketPharma M&A Targets (Metabolic Disease Biotechs)
Novo Nordisk's $5.2 billion acquisition of Akero Therapeutics highlights a strategic push into the MASH treatment market. This deal could trigger a wave of similar acquisitions, boosting the value of other biotech firms with promising drugs for metabolic diseases.
Published: 10 October 2025
Explore BasketMASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: 21 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Upcoming trial readouts and regulatory steps can drive volatility; positive data may boost shares, but clinical setbacks can reverse gains.
Small-Molecule Focus
Work on novel small-molecule therapies could offer targeted advantages and partnership potential, though early science brings execution and safety risks.
Market And Size
With a market cap near $110M the stock is small and can be illiquid, which may amplify price moves and increase trading risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
